BioCryst Pharmaceuticals To Present New Peramivir Data at the 51st Annual ICAAC Meeting

BioCryst Pharmaceuticals BCRX today announced the presentation of data related to intravenous peramivir for the treatment of influenza at the 51st Annual Interscience Conference on Antimicrobial Agents & Chemotherapy in Chicago, Illinois. Data from the Company's completed Phase 3 safety and virology study—one of the largest, prospective studies of an influenza anti-viral in the hospital setting completed to date—will be presented as an oral presentation today, September 17, 2011 at 4:45 p.m. Central Time. The study was an open-label, randomized trial of the anti-viral activity, safety and tolerability of i.v. peramivir administered either as a once-daily infusion of 600 mg or a twice-daily infusion of 300 mg to adult and adolescent patients hospitalized with confirmed or suspected influenza infection. Treatment was planned for 5 days with an extension to 10 days in patients who needed additional treatment. Top-line results from this study were announced in January 2011. The oral presentation “Safety and Anti-viral Effect of Multi-Day Therapy with IV Peramivir 300 mg BID or 600 mg QD in Hospitalized Influenza Subjects” (Presentation Number V-402) concludes that the two regimens studied were generally safe and well-tolerated in patients hospitalized with influenza. Furthermore, no differences were observed between the two groups for the primary virology endpoint, which was the change (reduction) in influenza virus titer measured by log10 tissue culture infective dose (TCID50), as well as for the secondary virology endpoint studied (change from baseline in quantitative Polymerase Chain Reaction). There were no meaningful differences between the groups with respect to the other clinical or virologic endpoints.